Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inozyme Pharma

0.9794
+0.05996.51%
Volume:376.19K
Turnover:357.71K
Market Cap:62.92M
PE:-0.60
High:1.00
Open:0.9139
Low:0.8953
Close:0.9195
Loading ...

Company Profile

Company Name:
Inozyme Pharma
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
67
Office Location:
321 Summer Street,Suite 400,Boston,Massachusetts,United States
Zip Code:
02210
Fax:
- -
Introduction:
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases in the United States. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein, which is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Axel Bolte
President and Chief Executive Officer, Director
Douglas Treco
Chairman
Edward Mathers
Director
Lynne Sullivan
Director
Martin Edwards
Director
Reinaldo Diaz
Director
Robert Hopfner
Director
Sarah Bhagat
Director

Shareholders

Name
Position
Axel Bolte
President and Chief Executive Officer, Director
Henric Bjarke
Senior Vice President, Chief Operating Officer
Pedro Huertas
Senior Vice President, Chief Medical Officer
Stephen Basso
Senior Vice President, Finance
Steven Jungles
Senior Vice President, Chief Technical Operations Officer